Skip to main content
SpringerLink
Log in

Inflammatory Myofibroblastic Tumor

  • Chapter
  • First Online:
Soft Tissue Tumors

  • 123 Accesses

Abstract

Inflammatory myofibroblastic tumor is a neoplasm of intermediate biological aggressiveness and is classified among the fibroblastic—myofibroblastic tumors. It is also known as plasma cell granuloma, inflammatory myofibrohistiocytic proliferation, omental mesenteric myxoid hamartoma, inflammatory pseudotumor, inflammatory fibrosarcoma, and inflammatory myofibroblastic sarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    SMA: smooth muscle actin.

  2. 2.

    MSA: muscle-specific actin.

  3. 3.

    HHV8: human herpesvirus 8.

  4. 4.

    ALK-based fusion gene: ALK (anaplastic lymphoma kinase) encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. It plays an important role in the development of the brain. ALK has been found to be rearranged, mutated, or amplified in a series of tumors including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer.

  5. 5.

    Crizotinib: small molecule tyrosine kinase inhibitor targeting the following: ALK, MET.

  6. 6.

    Alectinib: small molecule tyrosine kinase inhibitor targeting the following: ALK.

  7. 7.

    Ceritinib: small molecule tyrosine kinase inhibitor targeting the following: ALK.

Suggested Readings

  • Brivio (2019) ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: efficacy and side effects. Pediatr Blood Cancer 66(5):e27645

    Article  Google Scholar 

  • Butrynski (2010) Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363(18):1727–1733

    Article  CAS  Google Scholar 

  • Casanova (2020) Inflammatory myofibroblastic tumor: the experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). Eur J Cancer 127:123–129

    Article  CAS  Google Scholar 

  • Fletcher (2020) WHO classification of tumours of soft tissue and bone, 5th ed.

    Google Scholar 

  • Fu (2019) Inflammatory myofibroblastic tumor: A demographic, clinical and therapeutic study of 92 cases. Math Biosci Eng 16(6):6794–6804

    Article  Google Scholar 

  • Honda (2019) Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. Investig New Drugs 37(4):791–795

    Article  CAS  Google Scholar 

  • Lee (2017) ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol 241(3):316–323

    Article  CAS  Google Scholar 

  • Michels (2017) ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. NPJ Precis Oncol 1(1):4

    Article  Google Scholar 

  • Mohammad (2018) ALK Is a specific diagnostic marker for inflammatory myofibroblastic tumor of the uterus. Am J Surg Pathol 42(10):1353–1359

    Article  Google Scholar 

  • Mossé (2017) Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children’s oncology group study. J Clin Oncol 35(28):3215–3221

    Article  Google Scholar 

  • Ogata (2019) Effectiveness of crizotinib for inflammatory myofibroblastic tumor with ALK mutation. Intern Med 58(7):1029–1032

    Article  Google Scholar 

  • Rao (2018) Inflammatory myofibroblastic tumor driven by novel NUMA1-ALK fusion responds to ALK inhibition. J Natl Compr Cancer Netw 16(2):115–121

    Article  Google Scholar 

  • Schöffski (2018) Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90,101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med 6(6):431–441

    Article  Google Scholar 

  • Taylor (2019) Morphologic overlap between inflammatory myofibroblastic tumor and IgG4-related disease: lessons from next-generation sequencing. Am J Surg Pathol 43(3):314–324

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery Oncology and Gastroenterology, University of Padova, Padova, Italy

    Simone Mocellin

  2. Melanoma and Soft Tissue Sarcoma Unit, Istituto Oncologico Veneto (IOV-IRCCS) of Padova, Padova, Italy

    Simone Mocellin

Authors
  1. Simone Mocellin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simone Mocellin .

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mocellin, S. (2021). Inflammatory Myofibroblastic Tumor. In: Soft Tissue Tumors . Springer, Cham. https://doi.org/10.1007/978-3-030-58710-9_133

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-58710-9_133

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-58709-3

  • Online ISBN: 978-3-030-58710-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation